FDG-PET Imaging in Veterinary Medicine: A Comprehensive Guide

Fludeoxyglucose F18 (FDG) is a radiopharmaceutical agent, a radioactive tracer that functions similarly to glucose and is used diagnostically with Positron Emission Tomography (PET) scans to pinpoint tissues with altered glucose metabolism in animals. It’s purely a diagnostic tool, not for therapy. Changes in glucose metabolism are significant indicators for various conditions, including malignancies, epilepsy, myocardial ischemia, inflammatory diseases, and neurological disorders like Alzheimer’s. A PET scan employs these radiotracers, administered before the scan, to visualize blood flow and metabolic activity within both healthy and diseased tissues. FDG, being a glucose analog, naturally concentrates in tissues with high glucose demands, such as tumors and areas of inflammation. This article provides a detailed overview of the applications of Fdg-pet Imaging in veterinary medicine, covering its mechanisms in different conditions, administration protocols, necessary precautions for animal patients, and crucial information for ensuring optimal imaging results and safety for both pets and veterinary staff.

Objectives:

• Understand the correct methods for administering fludeoxyglucose (F18) in veterinary patients.
• Recognize the importance of proper patient preparation in veterinary medicine before fdg-pet imaging.
• Detail the applications of FDG in diagnosing and monitoring various conditions in animals.
• Discuss strategies for veterinary healthcare teams to enhance coordination and communication to achieve high-quality images while maintaining safety standards in fdg-pet imaging.

Indications for FDG-PET Imaging in Animals

Fludeoxyglucose F18 (FDG) is a positron-emitting radiotracer essential for positron emission tomography (PET) in veterinary diagnostics, used to identify and monitor a range of conditions in animals. While conventional veterinary imaging techniques like X-rays, CT scans, and MRIs offer detailed views of tissue structure, they may not always detect functional abnormalities or early-stage diseases. Functional imaging, such as fdg-pet imaging, complements these structural methods by providing insights into metabolic activity at a cellular level. In veterinary fdg-pet imaging, the radiotracer FDG is administered to the animal, allowing visualization of blood flow, metabolic processes, and biochemical activities in both healthy and diseased tissues. FDG, mimicking glucose, accumulates in tissues with high glucose utilization, such as tumors and sites of inflammation, making it a powerful tool for detecting these conditions in animals.

Neurology: In veterinary neurology, fdg-pet imaging is invaluable for identifying areas of abnormal glucose metabolism in the brain. This is particularly useful in diagnosing and localizing seizure foci in animals with epilepsy. Furthermore, FDG-PET can help in visualizing metabolic changes associated with neurodegenerative diseases like cognitive dysfunction syndrome (CDS) in dogs, which is comparable to Alzheimer’s in humans, and in assessing brain trauma in animals. While not always an FDA-approved application in animals specifically (as approvals are often human-centric), the veterinary application is well-supported by research and clinical practice. [1][2][3]

Oncology: In veterinary oncology, fdg-pet imaging plays a crucial role in the diagnosis, staging, and monitoring of cancer treatment in animals. It is particularly effective for cancers that exhibit high glucose metabolism, such as lymphomas, carcinomas, and sarcomas, which are common in various animal species. Fdg-pet imaging aids in determining the extent of tumor spread, assessing treatment response, and detecting recurrence, making it an indispensable tool in managing cancer in pets. [4][5]

Cardiology: While less common than in human cardiology, fdg-pet imaging has applications in veterinary cardiology, particularly for research purposes and in specialized cases. It can be used to study myocardial metabolism in animals with heart disease, including cardiomyopathies and ischemic heart conditions. In research, it helps understand the metabolic changes in the heart under various pathological conditions.

Inflammatory Conditions and Infections: Fdg-pet imaging is highly sensitive in detecting inflammation and infection in animals due to the increased glucose metabolism in inflammatory cells and infectious agents. In veterinary medicine, this is particularly useful for identifying sites of infection that are difficult to locate with other imaging modalities, such as osteomyelitis, discitis, and soft tissue infections. It also aids in diagnosing and monitoring inflammatory conditions like immune-mediated diseases and certain types of arthritis in animals. [6][7]

Alt Text: FDG PET/CT scan illustrating lymphoma, showcasing the application of fdg-pet imaging in veterinary oncology for visualizing cancerous tissues with high metabolic activity.

Mechanism of Action of FDG in PET Imaging

The fundamental step in cellular glucose metabolism is catalyzed by hexokinases, enzymes with a high affinity for glucose, converting it to glucose-6-phosphate. This process establishes a concentration gradient that promotes glucose diffusion into cells via glucose transporters (GLUTs). The rapid phosphorylation by hexokinases traps glucose within the cell, as glucose-6-phosphate cannot readily diffuse out. In normal cells, glucose-6-phosphate is further metabolized. Fludeoxyglucose F18 (FDG) is structurally similar to glucose but lacks a hydroxyl group at the 2-C position, replaced by radioactive fluorine-18. Upon entering cells via GLUT transporters, FDG is phosphorylated but cannot be further metabolized. It accumulates intracellularly, requiring dephosphorylation by glucose-6-phosphatase to exit the cell. Tumor cells, however, typically have low levels of glucose-6-phosphatase. Furthermore, they exhibit increased glucose transporters and high glycolytic rates, leading to enhanced FDG uptake and retention compared to normal tissues. [8][9] Fdg-pet imaging detects this FDG accumulation through the radioactive decay of fluorine-18.

Positron emission tomography (PET), using radiotracers like [F18]FDG, measures glucose consumption rates in tissues by detecting radioactive emissions. Fluorine-18, with a half-life of approximately 110 minutes, emits positrons upon decay. These positrons annihilate upon collision with electrons in the tissue, converting mass into energy in the form of two photons (E=mc^2). PET scanners contain scintillation crystals that convert the energy from these photons into detectable electrical signals. [10]

Neoplastic Disease (Cancer): Metabolic changes in neoplastic cells often precede changes in tumor size, making fdg-pet imaging a vital tool in veterinary oncology for diagnosis and monitoring treatment response. [11] Cancer cells’ high demand for NADPH for synthesizing phospholipids, triglycerides, and proteins for rapid division drives increased aerobic glycolysis (Warburg effect). This process, producing lactate even in oxygen presence, is facilitated by increased glucose transporters, hexokinases, and decreased glucose-6-phosphatase. [12] Consequently, malignant cells show increased FDG uptake, detectable by PET. Fdg-pet imaging can also differentiate radiation necrosis from tumor recurrence and edema in animals post-radiation therapy. FDG uptake is reduced in edema, absent in necrosis, and elevated in tumors compared to healthy tissue, aiding in post-treatment monitoring in veterinary oncology. [13]

Epilepsy: The brain’s primary energy source is glucose. Alterations in glucose utilization patterns can indicate pathological conditions. In veterinary neurology, fdg-pet imaging can pinpoint seizure foci in animals with epilepsy. Seizure foci are hypermetabolic during seizures (ictal) and hypometabolic between seizures (interictal). Besides localization, FDG-PET provides insights into the overall functional status of the brain, aiding in comprehensive neurological assessments in veterinary patients. [14][2]

Neurodegenerative Diseases (e.g., Canine Cognitive Dysfunction): Fdg-pet imaging can help differentiate neurodegenerative conditions like Canine Cognitive Dysfunction Syndrome (CDS) from other behavioral or age-related issues in older dogs. Similar to Alzheimer’s in humans, CDS can manifest with reduced glucose metabolism in specific brain regions. Early detection of metabolic changes via fdg-pet imaging could be crucial for managing these conditions in animals, although treatment options are currently limited to supportive care. [3][1]

Myocardial Viability (Heart Health): In cardiac research and specialized veterinary cases, fdg-pet imaging can assess myocardial viability. Healthy myocardium primarily uses fatty acids for energy, but ischemic tissue shifts to glucose metabolism. FDG-PET can identify viable but ischemic myocardium in animals with heart disease. FDG accumulation in poorly perfused areas suggests reversible systolic dysfunction if blood flow is restored. This “perfusion-metabolism mismatch” is key. Conversely, “matched patterns” (low FDG and perfusion) indicate irreversible damage and low recovery potential post-revascularization. While relevant in research, clinical application in veterinary cardiology is still developing. [6][16]

Atherosclerosis: Fdg-pet imaging can visualize FDG uptake in atherosclerotic vessels, particularly in large arteries like the aorta. Increased macrophage activity in atherosclerotic plaques contributes to this uptake. Smooth muscle cells in arterial walls also show FDG uptake. While primarily a research tool in veterinary medicine, it can contribute to understanding vascular diseases in animal models. [17]

Infectious and Inflammatory Processes: Due to high glycolysis rates, inflammatory cells accumulate FDG. Fdg-pet imaging is valuable in detecting infection and inflammation sites in animals, especially orthopedic infections like osteomyelitis and prosthetic infections. It is also useful for diagnosing inflammatory conditions such as sarcoidosis, vasculitis, and inflammatory bowel diseases in animals, especially when standard diagnostics are inconclusive. [18][7]

Pharmacokinetics: FDG distributes rapidly throughout the body after intravenous administration in animals. It is transported into cells and phosphorylated to 18F-FDG-6-phosphate proportionally to tissue glucose metabolism. FDG clears from most tissues within 24 hours, though cardiac tissue clearance may take longer. Unmetabolized FDG is primarily excreted in urine. Understanding these pharmacokinetic properties is crucial for optimizing imaging protocols and interpreting results in veterinary fdg-pet imaging.

Administration of FDG in Veterinary Patients

FDG is administered intravenously 30 to 60 minutes before fdg-pet imaging. As a radioactive tracer, its radioactivity is measured in curies (Ci), or becquerels (Bq) in SI units. The radioactive decay factor, crucial for dose calculation, represents the fraction of the drug remaining after synthesis. Fluorine-18’s half-life of 110 minutes means the decay factor is 0.5 after 110 minutes. For veterinary patients, dosage is carefully calculated, often based on weight and species, to ensure optimal image quality while minimizing radiation exposure. Typical doses in veterinary medicine range from 2.5 to 7.5 mCi (92.5 to 277.5 MBq), adjusted for animal size and the specific imaging application. Precise dosage is determined by veterinary nuclear medicine specialists.

Patient Preparation for Veterinary FDG-PET Imaging

Proper patient preparation is paramount for high-quality fdg-pet imaging in veterinary medicine. Animals typically need to fast for 4 to 6 hours before FDG administration to minimize glucose levels, which can affect FDG uptake. Veterinary staff must ensure blood glucose is controlled, ideally through pre-scan laboratory testing and dietary management for at least two days prior. Elevated blood glucose can lead to suboptimal images. For cardiac studies in research settings, specific glucose loading protocols might be used under veterinary supervision, but this is not routine clinical practice. Animals should remain calm and inactive post-FDG injection, as muscle activity can lead to FDG accumulation in skeletal muscles, compromising image quality. Stress and hyperventilation should also be minimized to prevent unintended FDG uptake in the diaphragm and other muscles.

Special Considerations for Veterinary Patients

Patients with Hepatic or Renal Impairment: The pharmacokinetics of FDG in animals with hepatic or renal impairment are not extensively studied. In animals with renal dysfunction, altered FDG biodistribution, including decreased brain uptake and increased blood pool activity, might occur, potentially affecting image interpretation. Veterinary specialists must carefully evaluate image quality in these patients. [19]

Pregnancy Considerations: Fdg-pet imaging in pregnant animals requires careful benefit-risk assessment. Radiation exposure to the fetus is a concern. If fdg-pet imaging is necessary during pregnancy, protocols to minimize fetal radiation dose should be implemented. For non-emergency situations, timing the procedure to minimize potential fetal exposure is advisable, although specific guidelines for animals are not as defined as in human medicine. [20][7]

Lactation Considerations: Limited data exist on FDG excretion in animal milk. However, as a general precaution, temporary separation of mother and offspring post-FDG administration might be considered to minimize potential radiation exposure to young animals, although specific veterinary guidelines are needed. [7]

Diabetes Mellitus: Animals with diabetes mellitus should have their blood glucose well-regulated for at least two days before fdg-pet imaging. For oncological imaging, hyperglycemia can significantly interfere with FDG uptake in tumors, potentially causing false-negative results. While strict glucose control may be less critical for imaging inflammation, optimal glucose management generally improves image quality and diagnostic accuracy in veterinary fdg-pet imaging. [21][22]

Vaccination Status: The impact of recent vaccinations on fdg-pet imaging in animals is an emerging area of consideration. In humans, transient FDG uptake in lymph nodes post-COVID-19 vaccination has been observed. While veterinary-specific data is lacking, it’s prudent to consider recent vaccination history when interpreting lymph node uptake on fdg-pet imaging in animals, particularly in oncological contexts. [23][24]

Alt Text: Veterinary technician carefully positioning a dog for a CT scan, illustrating the meticulous preparation often required in veterinary imaging procedures like fdg-pet imaging to ensure accurate results.

Adverse Effects of FDG in Veterinary Medicine

Adverse reactions to FDG in veterinary patients are rare. However, vigilance is necessary. Isolated case reports in human medicine mention hyperglycemia or hypoglycemia, transient hypotension, and temporary increases in alkaline phosphatase. [25] Anaphylaxis, though extremely rare, has been reported in humans. In veterinary settings, monitoring for any signs of adverse reactions post-FDG administration is crucial. Veterinary facilities performing fdg-pet imaging must be equipped with emergency resuscitation equipment and trained personnel to manage potential anaphylactic reactions or other adverse events, although these are exceedingly uncommon. [26]

Contraindications for FDG-PET Imaging in Animals

Known contraindications for FDG administration in animals are minimal, primarily hypersensitivity to fludeoxyglucose or formulation components, which is exceptionally rare. Precautions mainly relate to radiopharmaceutical handling to minimize radiation exposure to veterinary staff and other animals within the facility. Specialized facilities and workflows are essential in veterinary nuclear medicine to ensure radiation safety. “Warm waiting areas” can help separate animals that have received FDG from other patients to further reduce potential radiation exposure to the general animal population in a veterinary hospital. [27]

Monitoring Post-FDG Administration in Veterinary Patients

Fdg-pet imaging is inherently a monitoring tool, visualizing glucose accumulation in metabolically active tissues. FDG biodistribution mirrors glucose metabolism, with high uptake in organs like the brain (in neurologically normal animals) and moderate uptake in the liver, spleen, and bone marrow. Active skeletal muscles also accumulate FDG. FDG is cleared from the body, mainly via urine, within 24 hours. In veterinary oncology and neurology, suboptimal imaging can occur in animals with uncontrolled blood glucose. Therefore, monitoring blood glucose and managing hyperglycemia pre-FDG administration are important to ensure optimal image quality and diagnostic accuracy in fdg-pet imaging. [28]

Toxicity of FDG

Formal animal studies specifically assessing the carcinogenic, mutagenic, or fertility effects of fludeoxyglucose are not extensively documented. However, clinical experience over decades in human and veterinary medicine suggests a very low risk profile for diagnostic doses of FDG. Radiation exposure from FDG is the primary consideration, which is minimized through careful dose calibration and radiation safety protocols in veterinary nuclear medicine facilities.

Enhancing Veterinary Healthcare Team Outcomes in FDG-PET Imaging

Integrating PET and CT imaging, often as PET/CT, significantly enhances diagnostic capabilities in veterinary medicine. PET detects metabolic changes, while CT provides detailed anatomical information. Combined PET/CT allows simultaneous acquisition, improving lesion localization accuracy. Fdg-pet imaging, utilizing radioactive FDG, necessitates a team approach focused on minimizing radiation exposure while maximizing image quality.

Optimizing Patient Preparation: Meticulous patient preparation is crucial for successful veterinary fdg-pet imaging [Level 1]. For morning scans, animals should have a light evening meal the night before, avoid alcohol (if relevant to the species and unlikely), and fast after midnight [Level 5]. For afternoon scans, a light, sugar-free breakfast before 8 am is permissible, and regular medications should be continued [Level 5]. Pre-hydration is beneficial, reducing artifacts and radiation exposure. Administering one liter of water (or appropriate volume for smaller animals) two hours pre-FDG injection helps minimize FDG concentration in the bladder, improving visualization of pelvic regions [Level 3]. While diuretics like furosemide can be used to reduce bladder activity, adequate pre-hydration is often sufficient [Level 5].

Post-FDG injection, animals must remain still and quiet to prevent muscle FDG uptake [Level 1]. Administering injections in a dimly lit, quiet environment can minimize brain activity, reducing non-specific brain FDG uptake, although this is less critical in sedated or anesthetized animals, which are often used in veterinary fdg-pet imaging [Level 3]. Maintaining patient warmth is important as brown fat can accumulate FDG if the animal is cold [Level 4]. Exercise should be restricted for at least 6 hours pre-injection, and transporting animals to the clinic by bicycle (or similar strenuous activity) immediately before the scan should be avoided [Level 5]. [29]

For diabetic animals, scheduling fdg-pet imaging for the late afternoon might be preferable to better manage glucose levels throughout the fasting period [Level 5]. Standard fasting protocols apply, and medications should be continued [Level 1]. Point-of-care blood glucose checks upon arrival at the veterinary imaging center can streamline workflow, avoiding delays if glucose levels are unsuitable [Level 5]. Blood glucose should be measured using a calibrated glucometer before FDG administration [Level 4]. While human guidelines often recommend rescheduling if glucose is > 120 mg/dL, veterinary protocols may be more flexible depending on the clinical context. Insulin administration to acutely lower blood glucose within 4 hours of FDG injection should be avoided for tumor imaging as it can increase muscle FDG uptake [Level 1]. [29]

In veterinary cardiology research, oral glucose loading followed by insulin might be used to enhance myocardial FDG uptake, but this is not standard clinical practice [Level 5]. [16] For inflammatory conditions, particularly vasculitis, if relevant to veterinary species, glucocorticoid withdrawal might be considered based on specific protocols, balancing diagnostic needs with patient management. [31] [Level 3]

When ordering fdg-pet imaging for veterinary oncology, providing comprehensive clinical information is essential for effective coordination and image interpretation [Level 5] [29]:

• Specific indication for the PET or PET/CT study.
• Animal’s weight and breed/size for accurate Standardized Uptake Value (SUV) calculations. Weight should be recent, especially for serial studies in cancer patients.
• Tumor type and location (if known).
• History of prior tumors and relevant comorbidities, especially inflammatory conditions.
• Results of previous imaging studies (radiographs, ultrasound, CT, MRI).
• Allergies.
• Diabetes mellitus and current medications.
• If monitoring treatment response, details of prior therapies (dates, types).
• Kidney function status.

Essential Materials for FDG Administration:

• A multi-port IV system for tracer administration and saline flush. Electronic infusion pumps can also be used [Level 5]. [29]
• Point-of-care glucose meter for quick glucose checks in animals prone to hyperglycemia. However, these meters may not be precise enough for SUV correction if needed. If rescheduling hyperglycemic animals is not feasible, calibrated laboratory glucose measurements might be necessary for SUV correction in serial studies [Level 1]. [32]
• Accurate veterinary weighing scales.

Crucial Clinical Information for Scan Interpretation:

• Detailed clinical history focusing on the presenting disease, location, diagnosis date, biopsy confirmation, previous treatments, and medications [Level 5]. [29]
• Relevant comorbidities, such as diabetes or concurrent inflammatory diseases.
• Thorough history of prior treatments, including steroids, surgery, radiation, chemotherapy, and immune-modulating therapies. For chemotherapy monitoring, a minimum interval of about ten days between chemotherapy and fdg-pet imaging is recommended, ideally scheduling the scan close to the next chemotherapy cycle.
• Required report turnaround time.
• Animal’s ability to remain still for the scan duration (typically 20-45 minutes) and tolerate positioning. Sedation or anesthesia is often required in veterinary patients.
• History of claustrophobia (less relevant in veterinary patients as sedation is common, but positioning tolerance is still important).

Preparation and Administration Protocols:

• Veterinary staff handling radiopharmaceuticals must have comprehensive, competency-based training covering dose dispensing, calibration, labeling, quality control, radiation safety, record-keeping, and aseptic techniques.
• Waterproof gloves and appropriate radiation shielding must be used when handling FDG to minimize radiation exposure to staff and the animal patient.
• An indwelling IV catheter is placed, and blood samples are collected for any pre-scan laboratory tests. A multi-way valve system is used for FDG injection and saline flush.
• For automated administration systems, ensure the administered FDG activity is within 3% of the intended dose.
• Position the animal comfortably and quietly. Encourage urination shortly before imaging to reduce bladder interference. [29]

Effective interprofessional collaboration is vital in veterinary fdg-pet imaging. A veterinary nuclear medicine specialist should ideally oversee PET/CT procedures. However, a board-certified veterinary radiologist with specialized nuclear medicine training can also supervise. A certified veterinary nuclear medicine technologist should perform the scans. A medical physicist (or similarly qualified expert) is essential for optimizing FDG PET/CT protocols, ensuring adherence to standards, radiation dose monitoring, and minimizing CT radiation burden. Close collaboration among referring veterinarians, nuclear medicine specialists, technologists, and physicists is crucial for optimal patient outcomes and radiation safety in veterinary fdg-pet imaging [Level 5]. [33]

Review Questions (Veterinary Specific)

1. What are the primary veterinary applications of fdg-pet imaging?
2. How does patient preparation differ for fdg-pet imaging compared to standard radiography in veterinary medicine?
3. What are the key considerations for administering FDG to diabetic animals undergoing fdg-pet imaging?
4. Describe the role of interprofessional collaboration in ensuring optimal outcomes in veterinary fdg-pet imaging.
5. What measures are taken to minimize radiation exposure to veterinary staff and animal patients during fdg-pet imaging procedures?

References

1.Tai YF, Piccini P. Applications of positron emission tomography (PET) in neurology. J Neurol Neurosurg Psychiatry. 2004 May;75(5):669-76. [PMC free article: PMC1763584] [PubMed: 15090557]

2.Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, Casella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979 Jan;44(1):127-37. [PubMed: 363301]

3.Newberg A, Alavi A, Reivich M. Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders. Semin Nucl Med. 2002 Jan;32(1):13-34. [PubMed: 11839066]

4.Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004 May;231(2):305-32. [PubMed: 15044750]

5.Otsuka H, Graham M, Kubo A, Nishitani H. Clinical utility of FDG PET. J Med Invest. 2004 Feb;51(1-2):14-9. [PubMed: 15000251]

6.Anagnostopoulos C, Georgakopoulos A, Pianou N, Nekolla SG. Assessment of myocardial perfusion and viability by positron emission tomography. Int J Cardiol. 2013 Sep 01;167(5):1737-49. [PubMed: 23313467]

7.Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, Israel O, Martin-Comin J, Signore A. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013 Apr;54(4):647-58. [PubMed: 23359660]

8.Avril N. GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med. 2004 Jun;45(6):930-2. [PubMed: 15181126]

9.Suolinna EM, Haaparanta M, Paul R, Härkönen P, Solin O, Sipilä H. Metabolism of 2-[18F]fluoro-2-deoxyglucose in tumor-bearing rats: chromatographic and enzymatic studies. Int J Rad Appl Instrum B. 1986;13(5):577-81. [PubMed: 3818323]

10.Berger A. How does it work? Positron emission tomography. BMJ. 2003 Jun 28;326(7404):1449. [PMC free article: PMC1126321] [PubMed: 12829560]

11.Groheux D. Role of Fludeoxyglucose in Breast Cancer: Treatment Response. PET Clin. 2018 Jul;13(3):395-414. [PubMed: 30100078]

12.Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016 Mar;41(3):211-218. [PubMed: 26778478]

13.Doyle WK, Budinger TF, Valk PE, Levin VA, Gutin PH. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr. 1987 Jul-Aug;11(4):563-70. [PubMed: 3496366]

14.Sarikaya I. PET studies in epilepsy. Am J Nucl Med Mol Imaging. 2015;5(5):416-30. [PMC free article: PMC4620171] [PubMed: 26550535]

15.Graff-Radford NR, Jones DT. Normal Pressure Hydrocephalus. Continuum (Minneap Minn). 2019 Feb;25(1):165-186. [PubMed: 30707192]

16.Khalaf S, Chamsi-Pasha M, Al-Mallah MH. Assessment of myocardial viability by PET. Curr Opin Cardiol. 2019 Sep;34(5):466-472. [PubMed: 31393420]

17.Rosenbaum D, Millon A, Fayad ZA. Molecular imaging in atherosclerosis: FDG PET. Curr Atheroscler Rep. 2012 Oct;14(5):429-37. [PMC free article: PMC3576137] [PubMed: 22872371]

18.Alavi A, Kung JW, Zhuang H. Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med. 2004 Jan;34(1):56-69. [PubMed: 14735459]

19.Minamimoto R, Takahashi N, Inoue T. FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues. Ann Nucl Med. 2007 Jun;21(4):217-22. [PubMed: 17581720]

20.Zanotti-Fregonara P, Jan S, Taieb D, Cammilleri S, Trébossen R, Hindié E, Mundler O. Absorbed 18F-FDG dose to the fetus during early pregnancy. J Nucl Med. 2010 May;51(5):803-5. [PubMed: 20395321]

21.Langen KJ, Braun U, Rota Kops E, Herzog H, Kuwert T, Nebeling B, Feinendegen LE. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993 Mar;34(3):355-9. [PubMed: 8441023]

22.Rabkin Z, Israel O, Keidar Z. Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis. J Nucl Med. 2010 Jul;51(7):1015-20. [PubMed: 20554733]

23.McIntosh LJ, Bankier AA, Vijayaraghavan GR, Licho R, Rosen MP. COVID-19 Vaccination-Related Uptake on FDG PET/CT: An Emerging Dilemma and Suggestions for Management. AJR Am J Roentgenol. 2021 Oct;217(4):975-983. [PubMed: 33646823]

24.Eifer M, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Shams J, Keret N, Gorfine M, Eshet Y. COVID-19 mRNA Vaccination: Age and Immune Status and Its Association with Axillary Lymph Node PET/CT Uptake. J Nucl Med. 2022 Jan;63(1):134-139. [PMC free article: PMC8717182] [PubMed: 33893188]

25.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Oct 15, 2023. Fludeoxyglucose F18. [PubMed: 30000776]

26.Lee DY, Lee JJ, Kwon HS, Moon WY, Jin SY, Lee SJ, Oh SJ, Ryu JS. An unusual case of anaphylaxis after fluorine-18-labeled fluorodeoxyglucose injection. Nucl Med Mol Imaging. 2013 Sep;47(3):201-4. [PMC free article: PMC4035188] [PubMed: 24900108]

27.Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, Glanville J, McIntosh H, Renehan A, Weller D, Dunlop M. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. [PMC free article: PMC4781061] [PubMed: 21958472]

28.Apostolova I, Lange C, Suppa P, Spies L, Klutmann S, Adam G, Grothe MJ, Buchert R., Alzheimer’s Disease Neuroimaging Initiative. Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1417-1422. [PubMed: 29502311]

29.Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ., European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54. [PMC free article: PMC4315529] [PubMed: 25452219]

30.Sprinz C, Zanon M, Altmayer S, Watte G, Irion K, Marchiori E, Hochhegger B. Effects of blood glucose level on 18F fluorodeoxyglucose (18F-FDG) uptake for PET/CT in normal organs: an analysis on 5623 patients. Sci Rep. 2018 Feb 01;8(1):2126. [PMC free article: PMC5794870] [PubMed: 29391555]

31.Slart RHJA., Writing group. Reviewer group. Members of EANM Cardiovascular. Members of EANM Infection & Inflammation. Members of Committees, SNMMI Cardiovascular. Members of Council, PET Interest Group. Members of ASNC. EANM Committee Coordinator. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1250-1269. [PMC free article: PMC5954002] [PubMed: 29637252]

32.Dai KS, Tai DY, Ho P, Chen CC, Peng WC, Chen ST, Hsu CC, Liu YP, Hsieh HC, Yang CC, Tsai MC, Mao SJ. Accuracy of the EasyTouch blood glucose self-monitoring system: a study of 516 cases. Clin Chim Acta. 2004 Nov;349(1-2):135-41. [PubMed: 15469866]

33.Vali R, Alessio A, Balza R, Borgwardt L, Bar-Sever Z, Czachowski M, Jehanno N, Kurch L, Pandit-Taskar N, Parisi M, Piccardo A, Seghers V, Shulkin BL, Zucchetta P, Lim R. SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0. J Nucl Med. 2021 Jan;62(1):99-110. [PMC free article: PMC8679588] [PubMed: 33334912]

Disclosures: Muhammad Ashraf declares no relevant financial relationships with ineligible companies.

Disclosures: Amandeep Goyal declares no relevant financial relationships with ineligible companies.